Why Investors Need to Watch Sarepta Therapeutics Inc.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 8:30AM CDT
Sarepta is a popular stock in the Fool community, but its inestors have had a tough run lately, watching shares lose half of their value in the past six months. A late-stage trial failure by a competing drug from GlaxoSmithKline and Prosensa ...
Sarepta Therapeutics on Cusp of Huge Eteplirsen News
at The Street - Tue Apr 08, 1:34PM CDT
Sarepta executives met again with FDA officials in March to nail down a regulatory path for the Duchenne muscular dystrophy drug eteplirsen. The company has promised to update investors about the outcome of the FDA meeting, but without saying exactly...
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Top Gainers Technical Data -- Research on BGC Partners, Sarepta Therapeutics, TripAdvisor, and LiveDeal
PR Newswire - Wed Apr 02, 6:59AM CDT
The US markets saw a positive sentiment on Tuesday, April 01, 2014, with the NASDAQ Composite closing at 4,268.04, up 1.64%, the Dow Jones Industrial Average ending the session at 16,532.61, up 0.46% and the S&P 500 edging 0.70% higher to finish the trading session at 1,885.52. During the session, gains in the Consumer Discretionary, Information Technology, and Industrials sectors positively impacted the broader market. A number of stocks saw large movements, including BGC Partners Inc. (NASDAQ: BGCP), Sarepta Therapeutics Inc. (NASDAQ: SRPT), TripAdvisor Inc. (NASDAQ: TRIP) and LiveDeal Inc. (NASDAQ: LIVE). Free technical research on BGCP, SRPT, TRIP and LIVE can be downloaded upon signing up at:
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014
Business Wire - Wed Mar 26, 2:22PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
Sarepta Therapeutics to Present Company Overview at the 2014 Needham Healthcare Conference
Business Wire - Wed Mar 26, 7:30AM CDT
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 2014 Annual Needham Healthcare Conference in New York, NY on Tuesday, April 8, 2014 at 12:10 p.m. Eastern Time. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline (SRPT)
GlobeNewswire - Sat Mar 22, 6:25AM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
Prosensa Rises on Encouraging Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:20PM CDT
Shares of Prosensa rose following the announcement of encouraging data from a phase II study on drisapersen.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014
Business Wire - Wed Mar 19, 3:33PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
Prosensa Muscular Dystrophy Data Send Stock Rising
at Investor's Business Daily - Tue Mar 18, 11:50AM CDT
Beleaguered biotech stock Prosensa (RNA) was up 8% in midday trading on the stock market today after the company reported new data on its Duchenne muscular dystrophy candidate late Monday. Earlier, Prosensa stock was up as much as 30%, to 8.80, a...
Prosensa Making the Best of Inconsistent Drisapersen Data
at The Street - Tue Mar 18, 10:03AM CDT
With its Big Pharma partner gone, Prosensa will probably try to conjure a good story to bring in front of the FDA.
Today’s Top Biotech Stories: Prosensa, Medivation, and Alcobra
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 18, 8:26AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at this three top stocks -- Prosensa , ...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- SRPT
GlobeNewswire - Fri Mar 14, 2:15PM CDT
Pomerantz LLP has filed a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
What Lies Ahead For Sarepta Therapeutics, Inc.?
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 14, 1:30PM CDT
Sarepta Therapeutics has been one roller coaster of a stock over the last year while waiting for the Food and Drug Administration to make up its mind about whether its Duchenne muscular dystrophy drug, eteplirsen, deserves an accelerated approval....
The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 13, 5:30PM CDT
Not every company in biotech land is loved by investors. In fact, many biotechs top the list of companies with high short interest as a percentage of float. As of the end of February, Myriad Genetics was the second-most shorted company as a...
'Fast Money' Recap: From Stocks to Bonds?
at The Street - Thu Mar 13, 4:00AM CDT
The trading panel discussed the S&P 500, copper and emerging markets.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline -- SRPT
GlobeNewswire - Fri Mar 07, 5:51PM CST
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company"
The Nasdaq's 5 Most Hated Stocks
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 07, 5:16PM CST
I actually had to do some digging to come up with the date of April 7, 2000 as the last time the technology-heavy Nasdaq Composite closed at a higher point than it did earlier this week. The broader market has been the beneficiary of a strong...
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Why Sarepta Therapeutics Inc. Might Have a Fighting Chance
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
In November, it looked like Sarepta Therapeutics had very little chance of getting an accelerated approval for its Duchenne muscular dystrophy drug eteplirsen. The company said the Food and Drug Administration did a 180, from being open to...